Attorney Jessica Paluch-Hoerman, founder of TruLaw, has over 28 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Oxbryta Sickle Cell Lawsuit claims are being filed against Pfizer by patients who have suffered severe side effects and injuries after taking Oxbryta (voxelotor).
Oxbryta Sickle Cell Lawsuits allege that Pfizer, the drug’s manufacturer, failed to adequately warn consumers and medical professionals about the potential dangers of the medication.
These lawsuits further allege that:
Approved initially to help manage sickle cell anemia by preventing red blood cells from assuming a sickle shape, Oxbryta has been linked to severe complications in post-clinical studies.
Patients and families affected by these adverse outcomes are seeking compensation for medical expenses, lost wages, pain and suffering, and, in the most tragic cases, wrongful death.
With the FDA’s recent advisory and Pfizer’s voluntary recall of Oxbryta, these lawsuits aim to hold the manufacturer accountable for what plaintiffs believe to be an oversight in patient safety.
Legal teams nationwide are actively investigating Oxbryta lawsuits on behalf of sickle cell patients and families impacted by its severe side effects.
These lawsuits are based on findings from two registry-based studies conducted in the U.S. and by the European Medicines Agency (EMA).
Rather than alleviating the anemia associated with sickle cell disease (SCD), Oxbryta caused significant harm in many patients, with severe side effects reported, including:
In response to these alarming side effects, Pfizer initiated a global, voluntary recall of Oxbryta on September 25, 2024. The FDA quickly followed with a public advisory on September 26, 2024, urging healthcare professionals to stop prescribing Oxbryta and advising patients to discuss alternative treatments with their physicians immediately.
However, as of August 2023, Pfizer’s labeling for Oxbryta failed to list these severe side effects.
Lawyers argue that this omission reflects a critical lack of transparency, leaving patients uninformed about the risks they were undertaking.
Attorneys specializing in product liability and pharmaceutical litigation are working with individuals and families affected by these side effects, aiming to secure compensation and accountability for Pfizer’s alleged negligence.
For patients who have experienced these side effects or for families who have lost loved ones, these legal actions represent a chance to seek justice and receive support for the physical, emotional, and financial toll taken by Oxbryta-related injuries.
A wrongful death suit was initiated on May 16 in California against Global Blood Therapeutics and Pfizer, alleging that their drug Oxbryta led to fatal medical outcomes for Bruce Ford, a Tennessee resident.
His widow, Diana Ford, filed the complaint claiming the medication contributed to a surge in vaso-occlusive crises (VOCs), ultimately triggering a stroke and his death in May 2024.
According to the legal filing, Bruce Ford began treatment with Oxbryta in September 2022.
Soon after, he experienced a notable rise in VOC episodes, culminating in a stroke during one such episode in April 2024.
The lawsuit asserts that the drug manufacturers failed to provide adequate warnings to patients and healthcare providers about the potential for increased VOC risks, thereby compromising patient safety.
Pfizer conducted a recall of Oxbryta in September 2024, prompted by multiple reports of similar adverse effects.
The lawsuit levels several charges including defective design, failure to warn, negligence, breach of express and implied warranties, and violations of the Tennessee Consumer Protection Act, underscoring the broader concerns around drug safety and manufacturer responsibility.
On May 19, 2025, a federal judge announced that a jury trial will commence on August 2, 2027, in a class action lawsuit targeting Global Blood Therapeutics (GBT) and its parent company, Pfizer.
The legal action stems from allegations concerning the now-recalled sickle cell treatment, Oxbryta.
Unlike the separate mass tort litigation, which addresses specific personal injury claims, this class action represents all individuals who took Oxbryta, regardless of whether they experienced harm.
The central accusation is that the drugmakers failed to sufficiently warn the public about significant safety concerns prior to the drug’s voluntary withdrawal from the market.
The plaintiffs seek both financial compensation and non-monetary remedies, citing a systematic failure to disclose known health risks associated with the medication.
Pretrial activities are currently in progress in the U.S. District Court, preparing the case for its 2027 trial.
If you or someone close to you experienced adverse effects after taking Oxbryta, you may be eligible to join the separate multidistrict litigation (MDL) for injury claims. Use the chatbot on this page to check your eligibility instantly.
At least eight lawsuits have been filed against Pfizer and Global Blood Therapeutics following the market withdrawal of Oxbryta, a sickle cell disease medication.
Plaintiffs allege the drug caused severe health complications, including painful vaso-occlusive crises (VOCs), kidney failure, stroke, and in some cases, death.
Oxbryta was pulled from the market in September 2024 after regulators determined that its risks outweighed its potential benefits.
Since then, two federal lawsuits and six state cases in California have been filed.
U.S. District Judge Trina L. Thompson, presiding over the federal cases in the Northern District of California, has scheduled the first Oxbryta trial for June 2027.
While that verdict will not directly impact all other lawsuits, it is expected to influence future Oxbryta settlement negotiations.
In the meantime, parties are exploring mediation as a potential path to early resolution.
The litigation continues to grow as more individuals come forward with claims of injury caused by the recalled drug.
If you or a loved one used Oxbryta (voxelotor) tablets for sickle cell disease and suffered complications, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to join others in filing an Oxbryta lawsuit today.
Pfizer is seeking to dismiss several lawsuits filed by individuals who used the recalled sickle cell disease drug Oxbryta.
The company argues that the claims are preempted by federal law and that the plaintiffs do not meet the requirements for class certification.
Oxbryta, originally approved by the FDA in 2019 and later acquired by Pfizer in 2022, was recalled in September 2024 following reports of serious side effects, including vaso-occlusive crises (VOCs), strokes, and fatalities.
Plaintiffs allege that Pfizer and Global Blood Therapeutics, the drug’s original developer, failed to adequately warn users about these risks.
In its motion to dismiss, Pfizer maintains that it is shielded from liability due to the FDA’s approval of the drug’s labeling and asserts other legal defenses.
The lawsuits also include claims of fraud and violations of various consumer protection laws.
Despite Pfizer’s attempt to end the litigation, plaintiffs continue to seek accountability for the harm caused by the recalled medication.
The court’s ruling on this motion could have significant implications for the future of the Oxbryta litigation.
If you or a loved one used Oxbryta (voxelotor) tablets for sickle cell disease and suffered complications, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to join others in filing an Oxbryta lawsuit today.
A federal judge has issued a scheduling order for the Oxbryta injury lawsuit, setting the trial date for June 7, 2027.
This case is expected to be the first federal trial addressing the serious side effects associated with Oxbryta, a drug introduced in 2019 by Global Blood Therapeutics to treat sickle cell disease.
The medication was designed to improve hemoglobin levels and help blood cells retain more oxygen.
However, after a series of concerning reports about severe complications, including strokes and vaso-occlusive crises, Pfizer, which acquired Global Blood Therapeutics in 2022, issued a global recall in September 2024.
One notable lawsuit filed in November 2024 involves a man who claims Oxbryta caused him to suffer a stroke and frequent vaso-occlusive crises, which result in severe pain, organ damage, and even death.
In February 2025, the court issued a case management and scheduling order for this specific lawsuit, outlining deadlines for completing fact and expert discovery by late 2025 and early 2026.
If you or a loved one used Oxbryta (voxelotor) tablets for sickle cell disease and suffered complications, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to join others in filing an Oxbryta lawsuit today.
Understanding Vaso-Occlusive Crises in Sickle Cell Disease
Vaso-occlusive crises (VOC) are one of the most severe complications of sickle cell disease (SCD), causing intense pain, hospitalizations, and long-term health issues.
VOC occurs when sickled red blood cells obstruct blood flow and deprive tissues of oxygen.
This process leads to tissue damage, organ failure, and increased risk of recurrent crises.
Studies show that VOC follows four stages, progressing from mild aching pain to severe tissue infarction and inflammation.
Many patients never reach resolution, as VOC often leads to secondary vaso-occlusive crises (sVOC), resulting in prolonged hospital stays, worsening symptoms, and life-threatening complications like acute chest syndrome.
Repeated VOC episodes contribute to chronic organ damage and reduced life expectancy in SCD patients.
Common complications include:
Oxbryta (voxelotor) was designed to reduce sickling of red blood cells and prevent VOC episodes by stabilizing hemoglobin.
However, emerging reports indicate that the drug may have caused severe complications for some patients.
Lawsuits allege that Oxbryta increased hemolysis (red blood cell breakdown), exacerbating anemia and triggering secondary VOC events.
Post-market surveillance linked the drug to worsened pain crises, heightened inflammation, and multi-organ damage.
Plaintiffs argue that patients were not adequately warned about these risks before taking Oxbryta.
If you or a loved one used Oxbryta (voxelotor) tablets for sickle cell disease and suffered complications, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to join others in filing an Oxbryta lawsuit today.
The Oxbryta Lawsuit is ongoing, with Pfizer facing a rising number of legal actions over its sickle cell treatment, Oxbryta, following the drug’s market withdrawal.
Plaintiffs claim that Pfizer knew of serious and life-threatening complications caused by Oxbryta but failed to update the drug’s label to include these risks.
According to the complaint, this failure rendered the drug “misbranded” under federal law, which mandates that drug labels must remain accurate as new scientific information becomes available.
The Oxbryta Lawsuit focuses primarily on economic damages, asserting that patients would have opted for alternative treatments or paid less for Oxbryta if the risks had been properly disclosed.
This case adds to the scrutiny Pfizer faces regarding its handling of the medication and the alleged harm it caused to patients.
If you or a loved one used Oxbryta (voxelotor) tablets and later experienced severe complications—such as vaso-occlusive crises, organ damage, stroke, kidney failure, or other life-threatening injuries—you may be eligible to pursue legal action for compensation.
Contact TruLaw for a free consultation, or use the chatbot on this page for a free case evaluation and to connect with our Oxbryta Lawyers.
An Illinois resident has filed a lawsuit against Global Blood Therapeutics, a Pfizer subsidiary, alleging that the sickle cell disease medication Oxbryta caused him to suffer a stroke and more frequent vaso-occlusive crises (VOCs).
The lawsuit, filed on October 23 in California Superior Court for San Francisco, follows Pfizer’s global recall of Oxbryta due to reports of serious complications among patients.
Oxbryta (voxelotor), approved in 2019 under the FDA’s accelerated approval program, was marketed as a pioneering treatment for sickle cell anemia, designed to improve hemoglobin levels and enhance oxygen retention in red blood cells.
Pfizer acquired Global Blood Therapeutics in 2022 and continued selling the drug at a high cost.
However, increasing reports of VOCs and patient deaths led to the recall last month after Pfizer identified a significant risk-to-benefit imbalance.
The plaintiff claims Oxbryta caused painful episodes that required blood transfusions and hospitalizations.
In recent weeks, he suffered a stroke, resulting in vision loss, the inability to drive, and other impairments.
After learning of the recall on September 25, he stopped using Oxbryta but has continued to experience VOCs and remains hospitalized.
The lawsuit alleges that Oxbryta’s manufacturer failed to conduct adequate pre-market testing or warn about serious risks, including higher VOC rates and fatalities observed during clinical trials, which were flagged by European regulators.
If you or a loved one has been affected by Oxbryta, it’s important to understand your legal options. Reports have raised concerns about the drug’s severe effects, particularly among children in clinical trials.
If you or a loved one used Oxbryta (voxelotor) tablets and subsequently experienced severe complications—such as vaso-occlusive crises, organ damage, stroke, kidney failure, or other life-threatening injuries—you may be eligible to pursue legal action for compensation.
Contact TruLaw for a free consultation.
Use the chatbot on this page for a free case evaluation and to get in touch with our Oxbryta Lawyers.
In a major development, Pfizer has announced the market withdrawal of Oxbryta, a drug used to treat sickle cell disease.
Originally prescribed to improve blood oxygen levels in patients, particularly children, Oxbryta has been under scrutiny after reports of adverse events during a Phase 3 clinical trial.
The trial, which involved young children, revealed a concerning mortality rate among participants taking Oxbryta compared to those in the placebo group, leading Pfizer to halt distribution.
This recall has prompted multiple lawsuits, raising serious concerns about the drug’s safety and its pre-approval clinical testing.
Although some cases have already been filed, there may be the potential for a Multidistrict Litigation (MDL) if additional lawsuits are brought forward.
However, due to the relatively small number of patients who used Oxbryta, this litigation may remain more limited in scale, rather than growing into a mass tort involving thousands of plaintiffs.
The Oxbryta recall highlights the critical need for comprehensive pre-market testing of new drugs, especially those intended for vulnerable populations like children.
If you or a loved one used Oxbryta (voxelotor) tablets and subsequently experienced severe complications—such as vaso-occlusive crises, organ damage, stroke, kidney failure, or other life-threatening injuries—you may be eligible to pursue legal action for compensation.
Contact TruLaw for a free consultation.
Use the chatbot on this page for a free case evaluation and to get in touch with our Oxbryta Lawyers.
The recent recall of Oxbryta, a widely used medication for sickle cell disease, has left patients and healthcare providers in a state of uncertainty.
The recall followed reports of increased pain crises and an alarming disparity in death rates among clinical trial participants, leading the manufacturer to conclude that the risks associated with the drug outweighed its benefits.
As a result, healthcare providers are advising patients to gradually taper off the medication rather than stopping abruptly, in order to avoid potential withdrawal complications.
While this guidance is not based on clinical data, it is considered the safest course of action under the circumstances.
Many patients have voiced concerns over losing access to a treatment they relied on to manage their condition.
This recall underscores the ongoing challenges in treating sickle cell disease, which predominantly affects Black Americans.
With limited treatment options and existing therapies often presenting significant drawbacks, the removal of Oxbryta from the market highlights the urgent need for better research, transparency, and support to ensure that patients have access to safe and effective treatments.
If you or a loved one used Oxbryta (voxelotor) tablets and subsequently experienced severe complications—such as vaso-occlusive crises, organ damage, stroke, kidney failure, or other life-threatening injuries—you may be eligible to pursue legal action for compensation.
Contact TruLaw for a free consultation.
Use the chatbot on this page for a free case evaluation and to get in touch with our Oxbryta Lawyers.
Oxbryta (voxelotor) is a prescription medication developed to treat individuals with sickle cell disease (SCD), offering a novel approach as a hemoglobin S polymerization inhibitor.
Global Blood Therapeutics played a crucial role in developing Oxbryta.
This medication was designed to address the underlying cause of SCD by preventing red blood cells from assuming a sickle shape.
Oxbryta stabilizes red blood cells by binding to hemoglobin to improve their flexibility and reduce complications associated with SCD.
Available in tablet or liquid form, Oxbryta did not have a generic equivalent, and it was often prescribed alongside other treatments like hydroxycarbamide to reduce SCD-related complications, including pain episodes and blood transfusion requirements.
Sickle cell disease (SCD) is a genetic blood disorder characterized by the abnormal production of hemoglobin S, which affects the shape and function of red blood cells.
In SCD, the hemoglobin protein within red blood cells is abnormal, causing the cells to become rigid and assume a sickle or crescent shape.
These misshapen cells can block blood flow as they travel through the blood vessels, limiting oxygen delivery to tissues and organs.
This restricted circulation can result in a range of severe complications, including frequent infections, acute chest syndrome, and an increased risk of stroke.
Additionally, sickle cells have a shorter lifespan than normal red blood cells, leading to chronic anemia and fatigue in individuals with SCD.
Oxbryta was designed to prevent these complications by inhibiting hemoglobin polymerization, which causes red blood cells to sickle.
By reducing the formation of sickle-shaped cells, Oxbryta was intended to decrease the occurrence of vaso-occlusive crises (VOCs), a painful complication resulting from blocked blood flow, and improve overall blood flow and oxygenation for SCD patients.
Oxbryta was specifically targeted toward patients with sickle cell disease, particularly those who were at high risk of complications due to frequent VOCs or chronic anemia.
Approved for individuals aged 4 years and older, the medication was developed to address the unique needs of populations disproportionately affected by SCD, such as those of African, Mediterranean, Middle Eastern, and South Asian descent.
Given the limited treatment options for SCD, Oxbryta represented an important therapeutic advancement for managing SCD complications without the invasiveness of treatments like blood transfusions.
The ideal patient population for Oxbryta included:
By stabilizing hemoglobin and preventing cell deformation, Oxbryta provided a targeted treatment option to reduce both the daily symptoms and long-term risks of sickle cell disease.
Oxbryta’s journey to FDA approval began with promising early clinical trials, culminating in its official approval on November 25, 2019.
Initially approved for adults and children 12 and older, Oxbryta represented a significant advancement in sickle cell disease (SCD) treatment in the United States.
FDA approval came through the agency’s accelerated approval pathway.
This mechanism allows drugs to reach patients sooner if early data suggests they may provide substantial benefits for serious or life-threatening conditions.
The drug’s approval was granted based on the pivotal phase 3 GBT-HOPE clinical trial results, demonstrating Oxbryta’s ability to increase hemoglobin levels and reduce red blood cell breakdown (hemolysis) in patients with SCD.
The FDA granted Oxbryta accelerated approval due to the positive outcomes of the phase 3 GBT-HOPE clinical trial.
This randomized, placebo-controlled study enrolled 274 participants with SCD and investigated Oxbryta’s potential to modify the course of the disease.
Results from the trial showed that Oxbryta increased hemoglobin levels and decreased hemolysis, indicating a promising disease-modifying effect.
Due to these findings, Oxbryta was approved under the accelerated pathway, allowing the drug to reach the market faster and meet the unmet needs of SCD patients.
Oxbryta received a second accelerated approval from the FDA in December 2021, this time for treating children aged 4 to 11.
This approval was supported by data from the HOPE-KIDS 1 trial, which further validated Oxbryta’s effectiveness in increasing hemoglobin levels in younger patients.
The success of these trials positioned Oxbryta as a valuable option in the SCD treatment landscape.
Since its initial U.S. approval, Oxbryta has expanded its reach globally, with approvals in multiple countries.
The European Medicines Agency (EMA) granted Oxbryta Priority Medicines (PRIME) designation and classified it as an orphan medicinal product for SCD treatment.
This designation is reserved for drugs that address serious conditions with limited treatment options, reinforcing Oxbryta’s role as a priority therapeutic for SCD.
Between 2019 and 2024, Oxbryta received approval in 35 countries, expanding patient access worldwide.
The accelerated approval pathway provided Oxbryta with faster market access, contingent on further post-marketing studies to confirm its clinical benefits.
Under this pathway, early evidence from trials like GBT-HOPE suggested Oxbryta’s potential as a disease-modifying drug, but real-world data and continued research were essential to validating these early results.
The FDA’s approval of Oxbryta under this process underscored the urgent need for effective SCD treatments.
These treatments provide a lifeline for patients with limited options while requiring continued monitoring to ensure safety and efficacy.
Post-clinical trial data has raised serious concerns about the safety profile of Oxbryta, with findings suggesting that the medication may increase the risk of vaso-occlusive crises (VOCs) and mortality in sickle cell disease (SCD) patients.
VOCs are severe, painful episodes caused by blocking blood flow due to sickled red blood cells—a complication that Oxbryta was initially intended to reduce.
However, recent data from pivotal phase 3 trials and patient reports indicate that Oxbryta may have exacerbated these complications.
This information led Pfizer to initiate a voluntary recall, as ongoing research seeks to clarify the potential links between Oxbryta use and these severe health outcomes.
The “Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease (HOPE Kids 2 Study)” was a phase 3 post-clinical trial designed to assess Oxbryta’s impact on children with SCD.
This randomized, double-blind, placebo-controlled study monitored children aged 2 to 15 using Oxbryta.
While initially scheduled to conclude in January 2025, the trial faced early termination due to preliminary findings.
Key findings from the HOPE Kids 2 study include:
These early findings contributed significantly to Pfizer’s decision to withdraw Oxbryta from the market, underscoring the need for extreme caution in pediatric applications of the drug.
The RESOLVE study, formerly known as the “Resolution of Sickle Cell Leg Ulcers With Voxelotor (RESOLVE),” investigated the effects of Oxbryta on SCD patients suffering from leg ulcers.
Patients in the RESOLVE study experienced severe pain due to vaso-occlusive crises, which significantly impacted their physical health and quality of life.
This phase 3 study targeted patients aged 12 and older, aiming to assess whether Oxbryta could help heal chronic ulcers—a painful and complex SCD complication.
Key findings from the RESOLVE study include:
The data from these studies continue to be examined as Pfizer, and regulatory agencies assess the full impact of Oxbryta on patient health to highlight the importance of rigorous postmarket monitoring for medications approved under the accelerated pathway.
On September 25, 2024, Pfizer announced a voluntary global withdrawal of Oxbryta (voxelotor), a medication used to treat sickle cell disease (SCD).
The withdrawal affects all markets where Oxbryta is approved.
Pfizer also suspended all active clinical trials and expanded access programs worldwide.
This decision stems from post-market data revealing serious safety concerns, including increased rates of vaso-occlusive crises (VOCs) and fatal events among Oxbryta patients.
Pfizer is now working with global regulatory authorities to investigate these incidents and better understand the drug’s risk profile.
Following Pfizer’s announcement, the FDA issued a public warning on September 26, 2024, advising patients, caregivers, and healthcare professionals of the market withdrawal and potential risks associated with Oxbryta.
The FDA instructed healthcare providers to cease prescribing Oxbryta immediately and urged patients currently taking the medication to consult with their doctors to discuss alternative treatments.
The FDA also encouraged reporting adverse events, such as VOCs or other serious side effects, to the FDA’s Adverse Event Reporting System (FAERS), helping monitor the drug’s ongoing safety profile.
Key points from the FDA’s Oxbryta warning include:
The FDA’s response emphasizes patient safety and underscores the importance of post-market surveillance for drugs approved under accelerated pathways.
Oxbryta was initially approved under the FDA’s accelerated approval pathway in 2019 and 2021, which required Pfizer to conduct post-market studies to confirm its clinical benefits and safety profile.
However, recent findings from these studies and real-world data raised serious concerns about the drug’s safety.
In the HOPE Kids 2 trial (NCT04218084), eight pediatric patients receiving Oxbryta died, compared to only two deaths in the placebo group.
Additionally, two real-world registry studies showed a higher frequency of VOCs among Oxbryta patients with SCD.
Key findings from post-market monitoring that led to Oxbryta’s withdrawal include:
This monitoring process highlights the importance of ongoing post-market evaluations to ensure that medications meet safety expectations and that any emerging risks are addressed promptly.
On September 26, 2024, the European Medicines Agency (EMA) also recommended the suspension of Oxbryta across European markets.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) initiated a review of trial data in July 2024 and expressed serious concerns over Oxbryta’s safety profile, particularly regarding increased uncertainties due to adverse events observed in recent studies.
The EMA’s recommendation effectively suspends Oxbryta’s authorization, marketing, and distribution until a full review of all available data is complete.
Key aspects of the EMA’s response include:
The EMA’s suspension reflects a cautious approach, emphasizing patient safety and thoroughly evaluating emerging safety issues.
This decision, along with the FDA’s warning and Pfizer’s voluntary withdrawal, underscores the global response to potential risks associated with Oxbryta.
Patients who took Oxbryta to manage sickle cell disease (SCD) and subsequently suffered serious complications may be eligible to file a lawsuit against Pfizer, the drug’s manufacturer.
These lawsuits allege that Pfizer failed to provide adequate warnings about the risks associated with Oxbryta, such as increased incidence of vaso-occlusive crises (VOCs), organ damage, and even death.
Establishing eligibility requires demonstrating a clear link between Oxbryta use and adverse health effects.
To qualify for an Oxbryta lawsuit, individuals must typically meet specific criteria that show their use of the medication led to serious health complications.
Patients who have experienced life-threatening side effects or their surviving family members may be eligible to pursue legal action.
The key eligibility criteria for filing an Oxbryta lawsuit include:
Additional factors such as the duration of Oxbryta usage, the time between treatment initiation or discontinuation, the occurrence of adverse events, and the severity of complications will be considered to strengthen the lawsuit.
For those who have suffered these serious complications or for families who lost a loved one, these eligibility criteria provide the basis for pursuing compensation.
Gathering comprehensive evidence is essential for building a strong Oxbryta lawsuit.
Your legal team will work closely with you to compile the documentation linking Oxbryta use to your injuries, establishing the extent of harm caused, and providing proof of damages.
Evidence commonly required for an Oxbryta lawsuit includes:
By working closely with your legal team to gather this evidence, you can create a compelling claim that thoroughly documents the impact of Oxbryta-related complications.
This documentation supports eligibility and strengthens your case by showing the full extent of the harm suffered, enhancing the likelihood of fair compensation for your injuries.
When filing an Oxbryta lawsuit, plaintiffs seek compensation for a variety of damages incurred due to severe health complications related to the drug.
If successful, plaintiffs may recover damages that provide financial relief for both economic losses and personal suffering.
These compensatory damages aim to address past and future expenses, as well as the emotional and physical toll experienced by patients and their families.
Additionally, punitive damages may be awarded if Pfizer is found to have acted negligently or recklessly in distributing and marketing Oxbryta.
Recoverable damages in an Oxbryta lawsuit may include:
In cases where Pfizer’s actions are deemed grossly negligent, plaintiffs may also pursue punitive damages.
These damages are intended to penalize the manufacturer and deter similar conduct in the future, potentially increasing the total compensation awarded.
Filing an Oxbryta lawsuit involves several key steps, which an experienced product liability attorney can guide you through to maximize the chances of a successful outcome.
Working with a legal team ensures that each phase of the lawsuit process is handled professionally, helping to build a strong case.
The main steps to file an Oxbryta lawsuit include:
After the trial, there may be additional steps, such as appeals.
You will receive the awarded damages if no appeal is filed and the case is successful.
An experienced attorney will continue to manage the post-trial process to ensure the compensation is distributed appropriately.
By following these steps, plaintiffs can pursue accountability and justice for the harm caused by Oxbryta, with the potential to receive compensation that addresses the full scope of their injuries and losses.
Settlement amounts for Oxbryta lawsuits are expected to vary based on individual case factors, particularly the severity of health complications such as vaso-occlusive crises (VOCs) or fatal outcomes.
The specific circumstances of each plaintiff, including how injuries impacted their life, lost income, and medical costs, play a significant role in determining settlement values.
These ranges provide a general guideline, but actual payouts may differ widely based on individual case evaluations.
While actual settlement amounts will depend on case specifics, estimated settlement ranges based on the type of injury include:
Consulting an attorney experienced in pharmaceutical product liability can help plaintiffs understand potential compensation amounts and strengthen their cases to maximize potential settlements.
The statute of limitations sets a time limit on filing an Oxbryta lawsuit and varies by state.
It typically ranges from 1 to 3 years from the date of injury or discovery of harm.
This deadline emphasizes the importance of consulting an attorney promptly after experiencing VOCs, organ damage, or other severe complications potentially linked to Oxbryta.
Key points about the statute of limitations for Oxbryta lawsuits include:
Early consultation with a legal team can help plaintiffs ensure their lawsuit is filed within the appropriate time frame.
Missing the statute of limitations deadline could bar a plaintiff from recovering compensation, so timely action is important to protect your legal rights.
Oxbryta lawsuits are being filed by individuals across the country who were diagnosed with severe anemia after taking the medication.
TruLaw is currently accepting clients for the Oxbryta lawsuit.
A few reasons to choose TruLaw for your Oxbryta lawsuit include:
If you or a loved one suffered from severe anemia after taking Oxbryta, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Oxbryta lawsuit today.
The Oxbryta lawsuit involves patients filing claims against Pfizer for failing to adequately warn about severe side effects of the sickle cell disease medication.
Patients who experience vaso-occlusive crises (VOCs), organ failure, strokes, and other complications are seeking compensation for medical expenses and damages.
Patients who took Oxbryta and experienced serious complications like VOCs, organ damage, or stroke may qualify to file a lawsuit against Pfizer.
Family members can also file wrongful death claims if their loved one passes away due to complications related to Oxbryta use.
Oxbryta lawsuit settlements may range from $50,000 to over $1 million, depending on the severity of injuries and complications.
Recoverable damages include medical expenses, lost wages, pain and suffering, and, in fatal cases, wrongful death compensation.
Due to safety concerns revealed in post-market studies, Pfizer announced a voluntary global withdrawal of Oxbryta on September 25, 2024.
The withdrawal followed findings of increased mortality rates in pediatric patients and higher frequencies of vaso-occlusive crises among users.
The statute of limitations for filing an Oxbryta lawsuit typically ranges from 1 to 3 years from the date of injury or discovery of harm, varying by state.
Promptly consulting with an experienced pharmaceutical litigation attorney ensures your claim is filed within the legal deadline.
Managing Attorney & Owner
With over 25 years of legal experience, Jessica Paluch-Hoerman is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share the most reliable, accurate, and up-to-date legal information with our readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Depo Provera Lawsuit claims are being filed by individuals who allege they developed meningioma (a type of brain tumor) after receiving Depo-Provera birth control injections.
A 2024 study found that women using Depo-Provera for at least 1 year are five times more likely to develop meningioma brain tumors compared to those not using the drug.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?